

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10524963	
	Filing Date		2005-02-18	
	First Named Inventor	David William Tonge		
	Art Unit	1614		
	Examiner Name	Leslie A. Royds		
	Attorney Docket Number	100815-1P US		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524963
Filing Date	2005-02-18
First Named Inventor	David William Tonge
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	100815-1P US

1	RANSON M, et al, "The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer", Eur J Cancer Suppl 2007, 112–113, 5(4) (Abstract 718).	<input type="checkbox"/>
2	RANSON M, et al, "The pharmacokinetic and tolerability profile of once-daily oral ZD4054 in Japanese and Caucasian patients with hormone-refractory prostate cancer", ECCO 14, Barcelona, Spain, 23–27 September 2007. Poster.	<input type="checkbox"/>
3	ROSANO L, et al, "Endothelin A receptor/beta-arrestin signaling is critical for ovarian cancer metastasis: novel molecular therapeutic applications", Eur J Cancer Supp 2008; 54, 6 (Abstract 168).	<input type="checkbox"/>
4	ROSANO L. et al, "Endothelin A receptor promotes ovarian cancer metastasis: implications for an effective targeted-therapy", Proc Am Assoc Cancer Res, 2008, 49:abst 2574.	<input type="checkbox"/>
5	ROSANO L. et al, "Endothelin A receptor promotes ovarian cancer metastasis: implications for an effective targeted-therapy", AACR Annual Meeting, San Diego, CA, USA, 12–16 April 2008. Presentation	<input type="checkbox"/>
6	ROSANO L. Et al, "β-Arrestin 1 as messenger of endothelin A receptor to mediate β-catenin signaling and epithelial to mesenchymal transition in human ovarian cancer cells", Proc Am Assoc Cancer Res, 2007, 48:abst 5636.	<input type="checkbox"/>
7	ROSANO L.A. et al, "Endothelin-1 promotes proteolytic activity of ovarian carcinoma", Clinical Science, August 2002, 306S-309S, 103 (Supplement 48).	<input type="checkbox"/>
8	ROSANO, L. et al, "Emerging role of β-arrestin in endothelin A receptor-mediated signaling in the metastatic progression of ovarian cancer: implications for an effective targeted therapy", AACR: Advances in cancer research: from the laboratory to the clinic. Jordan, 16–19 March 2008;abst PR15.	<input type="checkbox"/>
9	ROSANO, L. et al, "Emerging role of β-arrestin in endothelin A receptor-mediated signaling in the metastatic progression of ovarian cancer: implications for an effective targeted therapy", AACR: Advances in cancer research: from the laboratory to the clinic. Jordan, 16–19 March 2008;oral presentation.	<input type="checkbox"/>
10	ROSANO, L. et al, "ZD4054, a Potent Endothelin Receptor A Antagonist, Inhibits Ovarian Carcinoma Cell Proliferation", Experimental Biology and Medicine, 2006, 1132-1135, 231.	<input type="checkbox"/>
11	SMOLICH M. et al, "Specific endothelin A receptor antagonist ZD4054 reduces breast cancer cell migration and invasion and exhibits synergistic effects with aromatase inhibitors and fulvestrant", AACR: Advances in cancer research: from the laboratory to the clinic. Jordan, 16–19 March 2008; abst PR8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524963
Filing Date	2005-02-18
First Named Inventor	David William Tonge
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	100815-1P US

12	SMOLLICH M. et al, "Specific endothelin A receptor antagonist ZD4054 reduces breast cancer cell migration and invasion and exhibits synergistic effects with aromatase inhibitors and fulvestrant", AACR: Advances in cancer research: from the laboratory to the clinic. Jordan, 16–19 March 2008; presentation.	<input type="checkbox"/>
13	SMOLLICH, M. et al, "Targeting the endothelin system: novel therapeutic options in gynaecological, urological and breast cancers", Expert Rev. Anticancer Ther., 2008, 1481-1493, 8(9)	<input type="checkbox"/>
14	STENSLAND B. et al, "N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide (ZD4054 Form 1)", Acta Crystallogr Section E Structure Rep, 2004; o1817–o1819, 60(10).	<input type="checkbox"/>
15	SWAISLAND H. et al, "Clinical drug interactions with ZD4054 in healthy, male volunteers", 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain, 2–4 November 2007; abst P84.	<input type="checkbox"/>
16	SWAISLAND H. et al, "Clinical drug interactions with ZD4054 in healthy, male volunteers", 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain, 2–4 November 2007; poster.	<input type="checkbox"/>
17	VENUTI et al, "An Endothelin a Receptor Antagonist as New Antitumor Agent in HPV Associated Cervical Carcinoma", Asco Abstracts 2001.	<input type="checkbox"/>
18	VERHAR et al; "Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans", Brit. J. Clin. Pharmacology, 2000, 562-573, 49.	<input type="checkbox"/>
19	WARREN R. et al, "ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer", Expert Opin. Investig. Drugs, 2008, 1237-1245, 17(8).	<input type="checkbox"/>
20	WILLIAMS E.D., "The combination of a specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents bone metastasis", EORTC-NCI-AACR, Prague, Czech Republic, 7–10 November 2006. Poster.	<input type="checkbox"/>
21	WILLIAMS ED et al, "The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis", Mol Cancer Ther, 2007;6(12) Suppl II:abst A271.	<input type="checkbox"/>
22	WILLIAMS, E.D. et al, "The combination of a specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents bone metastasis," European Journal of Cancer Supplements, 2006, 15, Volume 4, No. 12.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524963
Filing Date	2005-02-18
First Named Inventor	David William Tonge
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	100815-1P US

23	WULFING P. et al, "ZD4054, a specific endothelin A receptor antagonist, reduces breast cancer cell migration and invasion and exhibits additive effects with aromatase inhibitors and fulvestrant", Mol Cancer Ther, 2007;6(12) Suppl II: abst A275.	<input type="checkbox"/>
24	WULFING P. et al, "ZD4054, a specific endothelin A receptor antagonist, reduces breast cancer cell migration and invasion and exhibits additive effects with aromatase inhibitors and fulvestrant", AACR-NCI-EORTC, San Francisco, USA, 22–26 October 2007. Poster.	<input type="checkbox"/>
25	ZONNENBERG B. et al, "The effect of ZD4054 on bone metastasis in patients with M1 hormone-resistant prostate cancer", Calcif Tissue Int, 2008; 82 (Suppl 1):S95 (Abstract P093).	<input type="checkbox"/>
26	ZONNENBERG B. et al, "The effect of ZD4054 on bone metastasis in patients with M1 hormone-resistant prostate cancer", ECTS (35th European Symposium on Calcified Tissues), Barcelona, Spain, 24–28 May 2008. Poster	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.